Pear Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Pear Therapeutics heeft een totaal eigen vermogen van $30.6M en een totale schuld van $27.4M, wat de schuld-eigenvermogensverhouding op 89.7% brengt. De totale activa en totale passiva bedragen respectievelijk $95.1M en $64.5M.

Belangrijke informatie

89.7%

Verhouding schuld/eigen vermogen

US$27.45m

Schuld

Rente dekkingsratio	n/a
Contant	US$59.27m
Aandelen	US$30.59m
Totaal verplichtingen	US$64.54m
Totaal activa	US$95.13m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Apr 17

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Aug 18

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Aug 03

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

May 21

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Apr 04

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Jan 10

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $73.0M ) PEAR.Q } overtreffen de korte termijn passiva ( $49.4M ).

Langlopende schulden: De kortetermijnactiva PEAR.Q ( $73.0M ) overtreffen de langetermijnschulden ( $15.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PEAR.Q heeft meer geld in kas dan de totale schuld.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van PEAR.Q de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Er zijn onvoldoende gegevens om te bepalen of PEAR.Q voldoende cash runway heeft op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of PEAR.Q voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Pear Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Consensus revenue estimates decrease by 11%

Price target decreased by 31% to US$3.67

Price target decreased by 31% to US$3.67

Price target increased by 9.8% to US$6.00

Pear Therapeutics, Inc. Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Pear Therapeutics, Inc. Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP

Pear Therapeutics, Inc. Approves Reduction in its Workforce by Approximately 59 Employees

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

Pear Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Price target decreased to US$6.23

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

Consensus forecasts updated

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pear Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2022

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Price target decreased to US$9.00

Pear Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$10.00

Pear Therapeutics Announces Three New Board Members

Pear Therapeutics, Inc. Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst at SLEEP 2022

Pear Therapeutics, Inc. Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using ReSET At Six Months

Pear Therapeutics, Inc. Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Pear Therapeutics, Inc. Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

First quarter 2022 earnings: Revenues exceed analyst expectations

Pear Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Pear Therapeutics, Inc. Announces the Inclusion of QuickMD in Telehealth Provider Experience Initiative

Pear Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Pear Therapeutics, Inc. Receives Safer Technologies Program Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pear Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Pear Therapeutics, Inc. Announces Availability of reSET and reSET-O in Spanish

Pear Therapeutics Reaffirms Revenue Guidance for the Full Year 2022

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

No independent directors

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven